芬吗通联合坤泰胶囊治疗围绝经期综合征疗效及对5-HT、NE、DA水平的影响

摘要/Abstract

摘要： 目的探讨芬吗通联合坤泰胶囊治疗围绝经期综合征疗效及对5-羟色胺（5-HT）、去甲肾上腺素（NE）、多巴胺（DA）水平的影响。方法选择2020年3月—2022年5月天水四零七医院80例围绝经期综合征患者作为研究对象,采用随机数表法将其分为对照组和试验组,每组40例。对照组予以芬吗通单药治疗,试验组予以芬吗通联合坤泰胶囊治疗。评价两组临床疗效及安全性,治疗前后检测性激素[雌二醇（E₂）、卵泡刺激素（FSH）、黄体生成激素（LH）]及神经递质（5-HT、NE、DA）水平。结果试验组总有效率明显高于对照组,差异有统计学意义（P<0.05）。治疗后,试验组E₂水平明显高于对照组,差异有统计学意义（P<0.05）,两组FSH、LH水平比较,差异无统计学意义（P>0.05）。治疗后,试验组NE、DA水平明显高于对照组,差异有统计学意义（P<0.05）,两组5-HT水平比较,差异无统计学意义（P>0.05）。试验组乳房胀痛发生率明显低于对照组,差异有统计学意义（P<0.05）。结论坤泰胶囊辅助芬吗通治疗围绝经期综合征的疗效好,安全可靠,可有效改善E₂水平及神经递质水平。

关键词: 围绝经期综合征, 芬吗通, 坤泰胶囊, 神经递质, 性激素

Abstract: Objective To investigate the efficacy of Fendong combined with Kuntai capsule in the treatment of perimenopausal syndrome and its influence on the levels of 5-hydroxytryptamine (5-HT), norepinephrine (NE) and dopamine (DA). Methods From March 2020 to May 2022, 80 patients with perimenopausal syndrome were divided into two groups with 40 cases in each group by random number table method.The control group was treated with fenmorton, and the experimental group was treated with Fenmorton combined with Kuntai capsule. The clinical efficacy and safety were evaluated. The levels of sex hormones [Estradiol (E₂), follicle-stimulating hormone (FSH), luteinizing hormone (LH)] and neurotransmitters [5-HT, NE, DA] were detected before and after treatment. Results The total response rate in the test group (97.50%) was significantly higher than that in the control group (80.00%) (P<0.05). The E₂ level in the post-treatment group was significantly lower than that in the control group (P<0.05), and the FSH and LH levels in the two groups (P>0.05). NE and DA levels in the posttreatment test group were significantly higher than those in the control group (P<0.05), and there was no difference in 5-HT levels between the two groups (P>0.05). Conclusion The treatment of perimenopausal syndrome has good curative effect, safe and reliable, and can effectively improve E₂ level and neurotransmitter level.

Key words: perimenopausal syndrome, femerton, kuntai capsule, neurotransmitter, sex hormone

中图分类号:

R588.6

蒙玉梅. 芬吗通联合坤泰胶囊治疗围绝经期综合征疗效及对5-HT、NE、DA水平的影响[J]. 中华养生保健, 2024, 42(10): 20-23.

MENG Yu-mei. Effect of Fendong Combined with Kuntai Capsule on Perimenopausal Syndrome and its Influence on 5-HT, NE and DA Levels[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(10): 20-23.

参考文献

[1] 韩锐,万丹,刘琳,等.芬吗通治疗绝经综合征患者疗效及对血清性激素水平和子宫内膜厚度的影响[J].中国妇产科临床杂志,2021,22(5):477-479.
[2] 张航清,马麟娟.谷维素联合芬吗通治疗围绝经期综合征的疗效及对患者血清神经递质和激素水平的影响[J].中国妇幼保健,2021,36(13):3121-3123.
[3] 李书艳,姜文. 坤泰胶囊联合芬吗通治疗更年期综合征的疗效及安全性[J]. 中国妇幼保健,2018,33(5):1100-1102.
[4] 中华中医药学会妇科分会.和颜、坤泰胶囊临床应用专家指导意见[J].中草药,2020,51(8):2075-2081.
[5] 谢幸,苟文丽.妇产科学[M].第8版.北京:人民卫生出版社,2013:364-367.
[6] 朱文锋. 中医诊断学[M].北京:人民卫生出版社,1999.
[7] 郑筱萸. 中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:29-36.
[8] 王天琳,胡诗宛,赵林华,等.基于CiteSpace的中医药治疗围绝经期综合征的可视化分析[J].中国医药导报,2023,20(3):20-23,28.
[9] 陈宇霞,潘菊华,黄世敬.从脑肾相济论围绝经期综合征[J].中医学报,2023,38(2):273-277.
[10] 周立捷,孙韬,杨婕,等.孙韬教授从“引火归元”论治乳腺癌类更年期综合征经验[J].现代中西医结合杂志,2022,31(10):1418-1422.
[11] 吴红艳,黄飞翔,贾涔琳,等.益癸方联合芬吗通治疗围绝经期综合征的疗效研究[J].世界中医药,2019,14(10):2660-2664.
[12] SUN A J, WANG Y P, GU B, et al.A multi-center,randomized, controlled and open clinical trial of Heyan Kuntai Capsule and hormone therapy in perimenopausal women[J]. Chin J Integr Med,2018,24(7):487-493.
[13] 代春伶,高慧,侯金萌,等.坤泰胶囊对实验性卵巢早衰大鼠卵巢功能和生殖功能的影响[J].药物评价研究,2019,42(10):1942-1949.
[14] 门晓亮,赵丽萍,杨杰,等.坤泰胶囊治疗围绝经期综合征的系统评价再评价[J].中国中药杂志,2021,46(19):5103-5109.
[15] 王丹,赵瑞珍,李小黎,等.益肾调气法对血管性痴呆模型大鼠脑单胺神经递质的干预作用[J].世界中医药,2020,15(10):1395-1399.
[16] 徐琼,高淑红.高淑红脑肾同治法治疗卵巢储备功能低下[J].中医学报, 2021,36(4):797-800.